Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosis.

Journal: Brain, behavior, & immunity - health

Volume: 37

Issue: 

Year of Publication: 

Affiliated Institutions:  Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, -- Inohana, Chiba, -, Japan.

Abstract summary 

Accumulating evidence suggests that the Epstein-Barr virus (EBV) plays a key role in the development of multiple sclerosis (MS). Additionally, depressive symptoms often precede the onset of MS. Given the role of the XBP1-sigma-1 receptor complex in the endoplasmic reticulum during EBV reactivation, the author proposes that fluvoxamine, an antidepressant with sigma-1 receptor agonism, could be a suitable therapeutic drug for MS.

Authors & Co-authors:  Hashimoto

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Aloisi F., Giovannoni G., Salvetti M. Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy. Lancet Neurol. 2023;22(4):338–349.
Authors :  1
Identifiers
Doi : 100752
SSN : 2666-3546
Study Population
Male,Female
Mesh Terms
Other Terms
Study Design
Study Approach
Country of Study
Publication Country
United States